Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prasugrel - Daiichi Sankyo/Eli Lilly and Company

Next Previous
Search
Drug Profile

Prasugrel - Daiichi Sankyo/Eli Lilly and Company

Alternative Names: CS-747; CS-747S; Effient; Efient; LY 640315; Prasugrel-hydrochloride; R 99224

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; Ube Industries
  • Developer Daiichi Sankyo Company; Eli Lilly; Eli Lilly and Company; Kurume University
  • Class Anti-ischaemics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Registered Stroke
  • Phase III Vaso-occlusive crisis
  • Phase II Ischaemic heart disorders

Most Recent Events

  • 18 Jan 2022 Prasugrel licensed to Cosette Pharmaceuticals in USA
  • 24 Dec 2021 Registered for Stroke (Prevention) in Japan (PO)
  • 24 Dec 2021 Registered for Stroke in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top